Oral Resveratrol Reduces Neuronal Damage in a Model of Multiple Sclerosis

Kenneth S. Shindler, Elvira Ventura, Mahasweta Dutt, Peter Elliott, Denise C. Fitzgerald, Abdolmohamad Rostami

Research output: Contribution to journalArticlepeer-review

141 Citations (Scopus)

Abstract

Background: Neuronal loss in multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE), correlates with permanent neurological dysfunction. Current MS therapies have limited the ability to prevent neuronal damage. Methods: We examined whether oral therapy with SRT501, a pharmaceutical grade formulation of resveratrol, reduces neuronal loss during relapsing-remitting EAE. Resveratrol activates SIRT1, an NAD-dependent deacetylase that promotes mitochondrial function. Results: Oral SRT501 prevented neuronal loss during optic neuritis, an inflammatory optic nerve lesion in MS and EAE. SRT501 also suppressed neurological dysfunction during EAE remission, and spinal cords from SRT501-treated mice had significantly higher axonal density than vehicle-treated mice. Similar neuroprotection was mediated by SRT1720, another SIRT1-activating compound; and sirtinol, an SIRT1 inhibitor, attenuated SRT501 neuroprotective effects. SIRT1 activators did not prevent inflammation. Conclusions: These studies demonstrate that SRT501 attenuates neuronal damage and neurological dysfunction in EAE by a mechanism involving SIRT1 activation. SIRT1 activators are a potential oral therapy in MS. © 2010 by North American Neuro-Ophthalmology Society.
Original languageEnglish
Pages (from-to)328-339
Number of pages12
JournalJournal of Neuro-Ophthalmology
Volume30
Issue number4
DOIs
Publication statusPublished - Dec 2010

ASJC Scopus subject areas

  • Clinical Neurology
  • Ophthalmology

Fingerprint

Dive into the research topics of 'Oral Resveratrol Reduces Neuronal Damage in a Model of Multiple Sclerosis'. Together they form a unique fingerprint.

Cite this